Figure 4

Reduced fibrosis and apoptosis in injured liver treated with MSCs + IL-6. A: Normal, B: CCl₄ injury, C: IL-6 treated, D: MSCs transplanted, E: IL-6 + MSCs transplanted, F: Graphical presentation of collagen levels (n=). CCl₄ vs IL-6 NS, CCl₄ vs MSCs ^#p< 0.05, ^##p< 0.01 and ^###p< 0.001, CCl₄ vs MSCs + IL-6 ^ɸ p< 0.05, ^{ɸ ɸ} p< 0.01 and ^{ɸ ɸ ɸ} p< 0.001, IL-6 vs MSCs + IL-6 ^ψp< 0.05, ^ψψp< 0.01 and ^ψψψp< 0.001, MSCs vs MSCs + IL-6 ^δp< 0.05, ^δδp< 0.01 and ^δδδp< 0.001. G-L Estimation of apoptosis in control fibrotic liver and treatment groups through TUNEL Assay. G: Normal, H: CCl₄ injury, I: IL-6 treated, J: MSCs transplanted, K: IL-6 + MSCs transplanted, L: Graphical presentation of apoptotic positive cells in different treatment groups (n=). CCl₄ vs IL-6 *p< 0.05, **p< 0.01 and ***p< 0.001, CCl₄ vs MSCs ^#p< 0.05, ^##p< 0.01 and ^###p< 0.001, CCl₄ vs MSCs + IL-6 ^ɸ p< 0.05, ^{ɸ ɸ} p< 0.01 and ^{ɸ ɸ ɸ} p< 0.001, IL-6 vs MSCs + IL-6 ^ψp< 0.05, ^ψψp< 0.01 and ^ψψψp< 0.001, MSCs vs MSCs + IL-6 ^δp< 0.05, ^δδp< 0.01 and ^δδδp< 0.001.